Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal´┐Ż
171.94
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 150.06 - 203.30
Open     -
Vol / Avg. 0.00/2.26M
Mkt cap 34.32B
P/E 58.87
Div/yield     -
EPS 2.92
Shares 199.58M
Beta 0.65
Inst. own 98%
Jul 22, 2015
Q2 2015 Alexion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 27, 2015
Alexion Pharmaceuticals Inc at Sanford C Bernstein Strategic Decisions Conference - 10:00AM EDT - Add to calendar
May 13, 2015
Alexion Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Alexion Pharmaceuticals Inc Annual Shareholders Meeting
May 6, 2015
Alexion Pharmaceuticals Inc at Deutsche Bank Health Care Conference
Apr 23, 2015
Q1 2015 Alexion Pharmaceuticals Inc Earnings Call
Apr 23, 2015
Q1 2015 Alexion Pharmaceuticals Inc Earnings Release
Mar 12, 2015
Alexion Pharmaceuticals Inc at Barclays Healthcare Conference
Mar 2, 2015
Alexion Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 15.21% 29.41%
Operating margin 17.27% 38.89%
EBITD margin - 43.10%
Return on average assets 8.50% 17.47%
Return on average equity 10.74% 23.11%
Employees 2,273 -
CDP Score - -

Address

352 Knotter Dr
CHESHIRE, CT 06410-1138
United States - Map
+1-203-7761790 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. (Alexion), is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. The Company is also evaluating other indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism, and it is progressing with other biotechnology product candidates in ultra-rare and severe disorders, which are in various stages of development.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
David L Hallal Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 48
Bio & Compensation  - Reuters
Dominique Monnet Senior Vice President, Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 50
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Age: 45
Bio & Compensation  - Reuters